Artal Group S.A. Denali Therapeutics Inc. Transaction History

Artal Group S.A.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$15.83 - $23.35 $4.75 Million - $7.01 Million	-300,000 Reduced 37.36%	502,899 $10.3 Million
Q1 2023 May 12, 2023	BUY	$21.91 - $32.67 $63,517 - $94,710	2,899 Added 0.36%	802,899 $18.5 Million
Q4 2022 Feb 13, 2023	BUY	$26.28 - $33.92 $5.26 Million - $6.78 Million	200,000 Added 33.33%	800,000 $22.2 Million
Q4 2021 Feb 11, 2022	BUY	$42.59 - $55.02 $4.26 Million - $5.5 Million	100,000 Added 20.0%	600,000 $26.8 Million
Q1 2021 May 14, 2021	BUY	$53.8 - $81.53 $5.38 Million - $8.15 Million	100,000 Added 25.0%	500,000 $28.6 Million
Q3 2020 Nov 13, 2020	SELL	$23.13 - $38.84 $1.16 Million - $1.94 Million	-50,000 Reduced 11.11%	400,000 $14.3 Million
Q2 2020 Aug 14, 2020	SELL	$16.01 - $28.82 $800,500 - $1.44 Million	-50,000 Reduced 10.0%	450,000 $10.9 Million
Q1 2020 May 14, 2020	BUY	$14.2 - $27.98 $1.42 Million - $2.8 Million	100,000 Added 25.0%	500,000 $8.76 Million
Q1 2019 May 10, 2019	SELL	$17.99 - $24.65 $1.8 Million - $2.47 Million	-100,000 Reduced 20.0%	400,000 $9.29 Million
Q2 2018 Aug 10, 2018	BUY	$15.25 - $21.02 $762,500 - $1.05 Million	50,000 Added 11.11%	500,000 $7.63 Million
Q1 2018 May 10, 2018	SELL	$15.36 - $24.8 $768,000 - $1.24 Million	-50,000 Reduced 10.0%	450,000 $8.86 Million
Q4 2017 Feb 09, 2018	BUY	$15.04 - $21.45 $7.52 Million - $10.7 Million	500,000	500,000 $7.82 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.